| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Amount of the cost of promissory notes accounted for as interest expense for debt | - | - | 158,730 | 114,512 |
| Total other income, net | 68,014 | -240,494 | 119,087 | 1,618,879 |
| Loss before income taxes | -922,723 | -2,041,272 | -2,220,661 | -662,026 |
| Loss from continuing operations, net of tax | -922,723 | -2,041,272 | - | - |
| Gain (loss) from discontinued operations | - | 500,816 | - | - |
| Gain from assignment of subsidiaries and vivus settlement | - | 6,973,302 | - | - |
| Net income (loss) | -922,723 | 5,432,846 | -2,220,661 | -662,026 |
| Preferred stock dividend and cash premiums | 231,210 | - | 1,051,695 | 216,798 |
| Preferred stock, accretion of redemption discount | - | - | 1,974,359 | 1,856,095 |
| Net income (loss) available to common stockholders, basic | - | - | -5,246,715 | -2,734,919 |
| Net loss from continuing operations attributable to common stockholders | -1,153,933 | - | - | - |
| Earnings per share, basic | -0.03 | -1.29 | -0.53 | -0.37 |
| Earnings per share, diluted | -0.03 | -1.29 | -0.53 | -0.37 |
| Weighted average number of shares outstanding, basic | 42,284,502 | 25,922,503 | 9,829,793 | 7,388,107 |
| Weighted average number of shares outstanding, diluted | 42,284,502 | 25,922,503 | 9,829,793 | 7,388,107 |
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)